228760.KQ
Genomictree Inc.
KOE · Healthcare · Biotechnology · KR
KRW 10,510.00
−1.13%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.9B | 3.8B | 2.4B | 3.4B | 29.9B |
| Cost of Revenue | 4.1B | 3.7B | 3.1B | 3.7B | 5.8B |
| Gross Profit | (1.1B) | 73.4M | (726.6M) | (1.0B) | 24.0B |
| Operating Expenses | |||||
| R&D Expense | 3.3B | 3.8B | 4.9B | 4.4B | 5.4B |
| SG&A Expense | 3.4B | 1.8B | 2.5B | 2.9B | 16.1B |
| General & Admin Expense | 329.7M | 366.9M | 429.6M | 459.6M | 649.2M |
| Selling & Marketing Expense | 1.2B | 1.4B | 2.1B | 2.4B | 8.4B |
| Other Expenses | 4.8B | 5.8B | 7.1B | 9.0B | 89.3M |
| Total Operating Expenses | 10.6B | 11.4B | 14.6B | 16.3B | 21.6B |
| Cost and Expenses | 14.7B | 15.1B | 17.7B | 20.7B | 27.5B |
| Operating Income (EBIT) | (11.7B) | (11.3B) | (15.3B) | (17.3B) | 2.4B |
| Non-Operating | |||||
| Interest Income | 2.1B | 2.0B | 3.3B | 2.8B | 2.8B |
| Interest Expense | 249.6M | 338.1M | 294.6M | 2.1B | 5.4B |
| Net Interest Income | 1.9B | 1.7B | 3.0B | 2.8B | (2.6B) |
| Other Non-Op Income/Expense | 2.6B | 2.2B | 4.9B | 7.8B | (6.1B) |
| Non-Operating Income (excl Interest) | (1.5B) | — | (5.2B) | (9.9B) | 716.5M |
| EBT (Pre-Tax Income) | (9.2B) | (9.1B) | (10.4B) | (9.5B) | (3.7B) |
| Income Tax Expense | 12.7M | 11.5M | 1.1M | (496.6M) | 2.5B |
| Bottom Line | |||||
| Net Income | (9.0B) | (9.0B) | (10.2B) | (8.8B) | (6.6B) |
| Earnings from Cont. Ops | (9.2B) | (9.1B) | (10.4B) | (9.0B) | (6.2B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (9.0B) | (9.0B) | (10.2B) | (8.8B) | (6.6B) |
| Per Share | |||||
| Basic EPS | (₩375) | (₩374) | (₩429) | (₩391) | (₩316) |
| Diluted EPS | (₩375) | (₩374) | (₩429) | (₩391) | (₩316) |
| Revenue Per Share | ₩123 | ₩156 | ₩99 | ₩153 | ₩1,423 |
| Shares | |||||
| Basic Shares Outstanding | 24.0M | 24.1M | 23.9M | 22.4M | 21.0M |
| Diluted Shares Outstanding | 24.0M | 24.1M | 23.9M | 22.4M | 21.0M |
| Profitability Metrics | |||||
| EBITDA | (13.2B) | (10.3B) | (9.0B) | (6.3B) | 3.0B |
| D&A | 1.1B | 1.0B | 1.1B | 1.2B | 1.3B |
| EBIT | (14.3B) | (11.3B) | (10.1B) | (7.4B) | 1.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026